X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA AUROBINDO PHARMA ALEMBIC PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 29.6 14.3 206.8% View Chart
P/BV x 6.8 3.7 183.8% View Chart
Dividend Yield % 0.7 0.4 164.2%  

Financials

 ALEMBIC PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
AUROBINDO PHARMA
Mar-17
ALEMBIC PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs792895 88.5%   
Low Rs443622 71.2%   
Sales per share (Unadj.) Rs167.0254.6 65.6%  
Earnings per share (Unadj.) Rs38.239.3 97.2%  
Cash flow per share (Unadj.) Rs42.046.6 90.2%  
Dividends per share (Unadj.) Rs4.002.50 160.0%  
Dividend yield (eoy) %0.60.3 196.6%  
Book value per share (Unadj.) Rs84.9160.0 53.1%  
Shares outstanding (eoy) m188.52585.88 32.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.73.0 124.1%   
Avg P/E ratio x16.219.3 83.8%  
P/CF ratio (eoy) x14.716.3 90.3%  
Price / Book Value ratio x7.34.7 153.4%  
Dividend payout %10.56.4 164.7%   
Avg Mkt Cap Rs m116,383444,390 26.2%   
No. of employees `000NA14.0 0.0%   
Total wages/salary Rs m4,21417,678 23.8%   
Avg. sales/employee Rs ThNM10,667.8-  
Avg. wages/employee Rs ThNM1,264.3-  
Avg. net profit/employee Rs ThNM1,645.8-  
INCOME DATA
Net Sales Rs m31,487149,157 21.1%  
Other income Rs m551,159 4.8%   
Total revenues Rs m31,542150,316 21.0%   
Gross profit Rs m10,06034,343 29.3%  
Depreciation Rs m7224,276 16.9%   
Interest Rs m37667 5.5%   
Profit before tax Rs m9,35630,558 30.6%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1607,597 28.4%   
Profit after tax Rs m7,19423,012 31.3%  
Gross profit margin %31.923.0 138.8%  
Effective tax rate %23.124.9 92.9%   
Net profit margin %22.815.4 148.1%  
BALANCE SHEET DATA
Current assets Rs m15,06692,062 16.4%   
Current liabilities Rs m7,67466,223 11.6%   
Net working cap to sales %23.517.3 135.5%  
Current ratio x2.01.4 141.2%  
Inventory Days Days67106 63.2%  
Debtors Days Days4168 60.0%  
Net fixed assets Rs m8,23762,919 13.1%   
Share capital Rs m377586 64.3%   
"Free" reserves Rs m15,41693,133 16.6%   
Net worth Rs m16,00593,719 17.1%   
Long term debt Rs m01,814 0.0%   
Total assets Rs m24,594162,494 15.1%  
Interest coverage x255.246.8 545.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.9 139.5%   
Return on assets %29.414.6 201.8%  
Return on equity %44.924.6 183.1%  
Return on capital %58.732.7 179.2%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,81175,838 23.5%   
Fx outflow Rs m5,31830,224 17.6%   
Net fx Rs m12,49345,613 27.4%   
CASH FLOW
From Operations Rs m9,30432,786 28.4%  
From Investments Rs m-3,105-17,870 17.4%  
From Financial Activity Rs m-1,959-19,153 10.2%  
Net Cashflow Rs m4,240-4,239 -100.0%  

Share Holding

Indian Promoters % 74.1 54.1 137.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 8.0 36.5%  
FIIs % 9.1 27.7 32.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.2 136.3%  
Shareholders   49,328 69,601 70.9%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS